Drug Profile
GSK 2878175
Alternative Names: GSK-175; GSK-175-A; GSK-2878175; GSK-8175Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; Regulus Therapeutics
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 28 Sep 2021 Discontinued - Phase-I for Hepatitis C (In volunteers) in Australia (PO)
- 28 Sep 2021 Discontinued - Phase-I for Hepatitis C (Treatment-naive) in Puerto Rico (PO)
- 28 Sep 2021 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in Greece (PO)